De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
10x Genomics Beheer
Beheer criteriumcontroles 4/4
De CEO 10x Genomics' is Serge Saxonov, benoemd in Jul2012, heeft een ambtstermijn van 12.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.29M, bestaande uit 6.6% salaris en 93.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.34% van de aandelen van het bedrijf, ter waarde $ 90.89M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.3 jaar en 5.5 jaar.
Belangrijke informatie
Serge Saxonov
Algemeen directeur
US$8.3m
Totale compensatie
| Percentage CEO-salaris | 6.6% |
| Dienstverband CEO | 12.3yrs |
| Eigendom CEO | 3.3% |
| Management gemiddelde ambtstermijn | 5.5yrs |
| Gemiddelde ambtstermijn bestuur | 5.5yrs |
Recente managementupdates
Recent updates
10x Genomics Is Still A Long Way From Profitability
Oct 03We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Sep 09
Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump
Aug 1010x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead
Jul 1010x Genomics: Sticking To The Plan To Avoid The Falling The Knife
Jun 21Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper
Jun 1410x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business
May 21Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price
Apr 15Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Feb 0510x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses
Jan 20Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%
Dec 22We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely
Nov 03Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Aug 04Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S
Jun 04At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?
Apr 2910x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate
Mar 24We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Feb 02Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?
Jan 12An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued
Dec 2210x Genomics: No Signs Of A Growth Turnaround, Heavy Bearish Momentum
Oct 12Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$240m |
| Mar 31 2024 | n/a | n/a | -US$264m |
| Dec 31 2023 | US$8m | US$545k | -US$255m |
| Sep 30 2023 | n/a | n/a | -US$223m |
| Jun 30 2023 | n/a | n/a | -US$172m |
| Mar 31 2023 | n/a | n/a | -US$174m |
| Dec 31 2022 | US$19m | US$504k | -US$166m |
| Sep 30 2022 | n/a | n/a | -US$167m |
| Jun 30 2022 | n/a | n/a | -US$142m |
| Mar 31 2022 | n/a | n/a | -US$89m |
| Dec 31 2021 | US$12m | US$430k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$455m |
| Jun 30 2021 | n/a | n/a | -US$504m |
| Mar 31 2021 | n/a | n/a | -US$533m |
| Dec 31 2020 | US$11m | US$400k | -US$543m |
| Sep 30 2020 | n/a | n/a | -US$134m |
| Jun 30 2020 | n/a | n/a | -US$78m |
| Mar 31 2020 | n/a | n/a | -US$49m |
| Dec 31 2019 | US$2m | US$394k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$100m |
| Jun 30 2019 | n/a | n/a | -US$105m |
| Mar 31 2019 | n/a | n/a | -US$105m |
| Dec 31 2018 | US$1m | US$366k | -US$112m |
Compensatie versus markt: De totale vergoeding ($USD 8.29M ) Serge } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.79M ).
Compensatie versus inkomsten: De vergoeding van Serge is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Serge Saxonov (47 yo)
12.3yrs
Tenure
US$8,286,050
Compensatie
Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$8.29m | 3.34% $ 78.9m | |
| Co-Founder | 12.3yrs | US$4.43m | 2.69% $ 63.5m | |
| Chief Legal Officer | 7.3yrs | US$3.88m | 0.12% $ 2.8m | |
| Chief of Global Operations | less than a year | geen gegevens | geen gegevens | |
| Founding Scientist & CTO | 2.8yrs | geen gegevens | geen gegevens | |
| Manager of Investor Relations and Strategic Finance | no data | geen gegevens | geen gegevens | |
| Chief People Officer | 3.8yrs | geen gegevens | geen gegevens | |
| Associate Director of Product Management | no data | geen gegevens | geen gegevens |
5.5yrs
Gemiddelde duur
49yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van TXG is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$8.29m | 3.34% $ 78.9m | |
| Co-Founder | 12.3yrs | US$4.43m | 2.69% $ 63.5m | |
| Independent Director | 4.6yrs | US$338.71k | 0.0038% $ 90.5k | |
| Independent Chairman | 11.2yrs | US$403.59k | 2.03% $ 47.9m | |
| Independent Director | 5.2yrs | US$336.39k | 0.0038% $ 90.5k | |
| Director | less than a year | geen gegevens | geen gegevens | |
| Independent Director | 7.2yrs | US$331.39k | 0.14% $ 3.4m | |
| Independent Director | 5.5yrs | US$346.39k | 0.029% $ 695.1k | |
| Director | less than a year | geen gegevens | geen gegevens |
5.5yrs
Gemiddelde duur
54.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TXG wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).